Cirrhosis Awareness Key to Improving Liver Health in NASH


Published by:

Source: Healio interview

Disclosures: Lawitz does not report any relevant financial disclosures.

We have not been able to process your request. Please try again later. If you continue to experience this problem, please contact [email protected]

In an exclusive video with Healio Gastroenterology, Eric Lawitz, MD, from the Texas Liver Institute, The University of Texas Health, San Antonio, reported on the NAVIGATE trial in cirrhosis associated with non-alcoholic steatohepatitis.

This is a phase 2b / 3 trial evaluating the use of belapectin in patients with NASH cirrhosis and portal hypertension who have not yet developed esophageal varices.

“This trial demonstrated that in patients without esophageal varices at baseline, belapectin had a statistically significant reduction in the absolute and percentage change in the hepatic portal venous gradient,” he said. was launched to improve patient and physician awareness of NASH cirrhosis as well as to obtain information about the NAVIGATE trial.


Comments are closed.